Oragenics announces 1-for-60 reverse stock split

Oragenics announced that its Board of Directors on December 22, 2022 approved a 1-for-60 reverse stock split of the company’s issued and outstanding shares of common stock, par value $0.001 per share, accompanied by a corresponding decrease in the company’s authorized shares of common stock, such that, following the consummation of the Reverse Stock Split, the number of authorized shares of common stock will be reduced from 250,000,000 shares to 4,166,666 shares. As a result of the Reverse Stock Split, the company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on January 23, 2023.